Recent advances in biosensor technology in assessment of early diabetes biomarkers
Abstract
Discovery of biosensors has acquired utmost importance in the field of healthcare. Recent advances in biological techniques and instrumentation involving nanomaterials, surface plasmon resonance, and aptasensors have developed innovative biosensors over classical methods. Integrated approaches provided a better perspective for developing specific and sensitive devices with wide potential applications. Type 2 diabetes mellitus is a complex disease affecting almost every tissue and organ system, with metabolic complications extending far beyond impaired glucose metabolism. Although there is no known cure for Type 2 diabetes, early diagnosis and interventions are critical to prevent this disease and can postpone or even prevent the serious complications that are associated with diabetes. Biomarkers for type 2 diabetes are useful for prediction and intervention of the disease at earlier stages. Proper selection of biomarkers that represent health and disease states is vital for disease diagnosis and treatment by detecting it before it manifests. In this respect, we provide an overview of different types of biosensors being used, ranging from electrochemical, fluorescence-based, nanomonitors, SPR-based, and field-effect transistor biosensors for early detection and management of diabetes with focus on prediabetes. In the future, novel non-invasive technologies combined with blood and tissue-based biomarkers will enable the detection, prevention, and treatment of diabetes and its c…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Blood glucose concentration and HbA1c are still the major biomarkers for both diagnosis and patient monitoring.
“Even though a variety of predictive, diagnostic, and prognostic biomarkers (and related technologies) are continuously proposed, blood glucose concentration and HbA1c are still the major biomarkers for both diagnosis and patient monitoring 36,37.”
From Glucose biosensors in clinical practice: principles, limits and perspectives of currently used devices (2022) · cites this paper as [36]
The citation lists haven’t been fetched yet
References 216 · Cited by 174
- Authors
- Salek-Maghsoudi, A., Vakhshiteh, F., Torabi, R., Hassani, S., Ganjali, M. R., Norouzi, P., Hosseini, M., & Abdollahi, M.
- Affiliations
- Tehran University of Medical Sciences (IR)
- University of Tehran (IR)
- Corresponding author
- Abdollahi, Mohammad
- ORCID
- Venue
- Biosensors and Bioelectronics
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 99
- Pages
- 122-135
- ISSN
- 0956-5663 (ISSN-L)
- OpenAlex
- W2739340421
- Cited by
- 174
- References
- 216
- Citations by year
- 2026: 4 · 2025: 16 · 2024: 24 · 2023: 18 · 2022: 20 · 2021: 26 · 2020: 24 · 2019: 26 · 2018: 14 · 2017: 2
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biosensors and Bioelectronics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Iran National Science Foundation
- National Institute for Medical Research Development
- Topics
- Physical Sciences › Engineering › Electrical and Electronic Engineering › Electrochemical sensors and biosensors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Physical Sciences › Engineering › Biomedical Engineering › Biosensors and Analytical Detection
- Keywords
- biosensors, type 2 diabetes, diabetes biomarkers, prediabetes, early diagnosis, surface plasmon resonance, aptasensor, electrochemical biosensor, fluorescent biosensor, field-effect transistor biosensors, nanomaterials, non-invasive detection, blood biomarkers, tissue biomarkers
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Biosensing Techniques, Biomarkers, Surface Plasmon Resonance, Early Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review